Journal of Integral Sciences [JIS]
[An International Open Access Journal]
Available at www.jisciences.com ISSN: 2581-5679

A Review on Medication Delivery Using Resealed Erythrocytes

Yanamala Srilakshmi*, Garnepudi Swathi, Nuthakki Suresh and Chandu Babu Rao.
Priyadharshini Institute of Pharmaceutical Education and Research, 5th mile, Pulladigunta, Guntur-522017. Andhra Pradesh, India.

Received: 05 June 2024 Revised: 10 July 2024 Accepted: 15 August 2024

Abstract
Cellular carriers, out of all the carriers that are used to target medications to different bodily tissues, satisfy a number of requirements that are desirable in clinical applications. The most crucial of these is that the carrier and its breakdown products must be biocompatible. platelets, fibroblasts, hepatocytes, erythrocytes, and nano erythrocytes, among other cells. The main obstacles to a successful industrialization are the therapeutic agents' quality control, process validation, and production scalability. Re-sealed erythrocytes are a unique drug delivery method that is now needed to solve this issue and increase patient compliance and efficiency. The isolation of carrier erythrocytes, drug loading techniques, parameter characterization techniques, and clinical uses of resealed erythrocytes were discussed in this review. "Resealed erythrocytes" are carriers that are created after the cells are broken up and the medication is attached to them using a few different techniques. Businesses now have the chance to cover a wide range of ailments for which there are presently no effective medicines because they have already completed many of the crucial clinical phases.

Keywords: erythrocytes, hepitocytes, and fibroblasts, leuckocytes, platelets.

***Corresponding Author**
Yanamala Srilakshmi

DOI: https://doi.org/10.37022/jis.v7i3.90

Produced and Published by
South Asian Academic Publications

Introduction

Current pharmaceutical scenario is aimed at development of drug delivery systems which make the most of the drug targeting along with high therapeutic benefits for safe and effective management of diseases. Targeting of an active bio molecule from active drug delivery where pharmacological moderator directed definitely to its goal site.Drug targeting can be methods by either chemical modification otherwise by suitable carrier. Numerous carriers has been used for the drug targeting amongst which cellular carrier offer a better potential benefits associated to its biodegradability, non-pathogenicity, non-immunogenicity, bio compatibility as well as self-degradability along with high drug loading efficiency. Leukocytes, platelets and erythrocytes have been proposed as cellular carrier organizations [1]

Blood contains different type of cells like erythrocytes (RBC), leukocytes (WBC) and platelets, among them erythrocytes are the most interesting carrier and possess excessive potential in drug delivery due to their capability to circulate all over in the body zero order kinetics, reproducibility and ease of preparation primary aim for the development of this drug delivery system is to maximize therapeutic performance, reducing undesirable side effects of drug and increase patient obedience. They may be classified based on their size as (i) micro carriers for example, Liposomes, re associated erythrocytes, micro spheres (ii) Nanoparticles for example, liposomes, pharmacopoeia, quarrelsome, nanoparticles, solid lipid nanoparticles (SLN), isosceles (iii) variable carriers for example, dendrites [2].

Erythrocytes:

Red blood cells are the most communal kind of blood cells and the vertebrate organism's main resources of delivering oxygen (O2) to the body tissues through the blood flow through the circulatory system. They receipt up oxygen in the lungs or gills and release it while squeezing via the body's capillaries [3].



Figure (1) Resealed Erythrocytes.

A globulin is a protein present in haemoglobin molecules, consist of four poly peptide chains; to each of the four chains, a non-protein pigment called a home is bound to it. It combines reversibly with one oxygen molecule; at the centre of the home ring allow each
haemoglobin molecule to bind four oxygen molecules. RBCs include water (63%), lipids (0.5), glucose (0.8%), mineral (0.7%), non-haemoglobin protein (0.9%), met haemoglobin (0.5%), and haemoglobin (33.67%) [4].

The cells develop in the bone marrow and circulate for about 100–120 days in the body before their components are recycled by macrophages. Each circulation takes about 20 seconds. Anatomy and physiology of RBC:



Figure (2) Anatomy and physiology of RBC.

Hypotonic pre swelled method:

It is based upon initial controlled swelling in a hypo-tonic buffered solution. This mixture is centrifuged at small g values. The supernatant is castoff and the cell fraction is carried to the lysis point by adding 100–120 µL portions of an aqueous solution of the drug to be encapsulated. After that the mixture is centrifuged between the drug-addition steps. The toxicity of a cell mixture is reinstated at the lysis point by adding a planned amount of hyper- tonic buffer. The lysis point is noticed by the disappearance of a distinct boundary between the cell fraction and the supernatant upon centrifugation. Finally, the cell suspension is incubated at 37 0C to renewal the resealed erythrocytes [5].

Hypotonic dialysis method:

This method was firstly reported by Klibansky in 1959 and was used in 1977 by DE loach and Millerand Dale for loading of enzymes as well as lipids. There are many procedures were based on the principle of semi permeable dialysis membrane which exploits the intracellular, extracellular volume ratio for macro-molecules throughout lysis and resealing. A desired hypocrite is attains in this course by mixing of erythrocyte suspension and drug solution. The mixture is hired into dialysis tubing and then both ends of tube are tied by thread. An air bubble of almost 25% of the internal volume is left in the tube. The tube was placed in the bottle containing 100ml of swelling solution. The bottle is placed at 4oC for the demand lysis Time. The contents of the dialysis tubing are mixed by means of shaking the tube using the strings. Then dialysis tube is placed in 100 ml of resealing solution [6].

Blood is actually made up of both cellular and liquid parts. Its components include approximately 45% red blood cells, less than 1% white blood cells and platelets, and about 55% plasma, which is the liquid portion. Therefore, blood cell formation is the replenishment of all cells of the blood, while red blood cell formation, also known as erythropoiesis, is the replenishment of only red blood cells.

Electric cell fusion method:

This method includes the early loading of suspended from the commencement of the experimentation. The typical pore diameter created in the membrane depends upon the intensity of electric field the discharge time, and the ionic strength of suspending medium. The colloid macro molecules contents of the cell may lead to cell lysis because of the increase in osmotic pressure. This process can be prevented by adding large molecules (e.g. tetra saccharide stachyose and bovine serum albumin) and ribonucleic. One advantage of this method is a more uniform distribution of loaded cells in comparison with osmotic methods [7].

Routes of administration:

The route of administration is the way through which the dosage form is administered into the body for treatment of various diseases and disorders. Various routes of administration play a marked Role in the bioavailability of the active drug in the body. In present review these routes are included with their advantages and limitations [8].

This is an attempt for the initials of field to familiarize with the routes of administrations with their significances. A route of administration in pharmacy is the path by which a drug is taken into the body Route, Bioavailability, Drug [9].

Applications of resealed erythrocytes:

Drug targeting:

Drug delivery should be site definite and target oriented to exhibit best therapeutic index with least adverse effects. It acts as drug carriers also targeting tools as well. It can be used to target RES organs as well as non-RES organs. To target organs of mono nuclear phagocytic organization/ RES Surface modified erythrocytes are used because the change in the membrane is known by macrophages [10].

Treatment of hepatic tumours:

Anti-neoplastic drugs like methotrexate, bleomycin, asparagine also Adriamycin have been effectively delivered by erythrocytes to cure hepatic tumours. Doxorubicin diffuses speedily from the cells upon loading and hence shows a problem which can be overwhelmed by covalently linking doxorubicin to the erythrocyte. Membrane using formaldehyde orcisaconitic acid as a spacer Removal of RES iron overloads: To treat excess iron gathered deferoxamine loaded Erythrocytes have been used since, of several transfusions to thalassotherapy patients [11]. This drug targeting to the RES is very helpful because the aged erythrocytes are destroyed inures organs, which results in an accretion of iron in these organs

Carriers for enzymes:

Carriers for enzymes: For this purpose enzymes can be vaccinated into the blood stream to substitute a missing or absent enzyme in metabolic disorders or to reduce toxic compounds accumulated in the blood due to a disease such as, environmental, lysosome storage disorders such as Gautier's disease, hyperglycaemia, hyperphenylalaninemia and kidney failure are only few examples of metabolic complaints that can be treated by supervision of enzymes

Phagocytosis cells have been used for in vitro to simplify the uptake of enzymes by phagolysosomes [12].

Iron cheaters For treatment of iron over accumulation in the thalassemia patients another forms of anaemia that require regular transfusions for that carrier erythrocytes, encapsulated with deferoxamine (DF), have been studied widely As discussed above, the RES is the main site of destruction of old erythrocytes and, consequently, of iron over-accumulation in these patients. A remarkable degree of targeting DF to RES using carrier erythrocytes has been reported [13].

Advantages of resealed erythrocytes:

The resealed erythrocytes should have the following advantages:

Their biodegradability with no generation of toxic products. He considerably uniforms size and shape of the carrier. Relatively inert intracellular environment [14]. Prevention of degradation of the loaded drug from inactivation by endogenous chemicals. The wide variety of chemicals that can be entrapped.

Disadvantages of resealed erythrocytes:

They have a limited potential as carrier to non- phagocyte target tissue. Possibility of clumping of cells and dose dumping may be there.

Erythrosomes:

Erythrosomes are specially engineered vesicular systems in which chemically cross-linked human erythrocytes cytoskeletons are used as sport upon which a lipid bilayer is coated. This can be achieved by a modification procedure normally adopted for reverse phase evaporation. Erythrosomes are proposed as useful encapsulation system for drug delivery particularly for macromolecular drugs [15]. Large (3, tm diameter) mechanically stable proteoliposomes (erythrosomes) International Journal of Pharmaceutical Sciences Review and Research were prepared in good yield by coating cross linked erythrocyte cytoskeletons with phosphatide choline.

The Nanoerythrosomes compositions further leads to the formation of bioassays. In case of Gautier's disease glucocortisone was encapsulated in erythrocytes and heparin was encapsulated in erythrocytes to prevent thromboembolism [16]. Preparation of (nEs) and drug loading



Figure (3) Nanoerythrosomes

Drug targeting to the RES organs:

The resulting chemically modified erythrocytes present a marked decrease in deformability and membrane fluidity. This membrane alteration reduces erythrocyte biocompatibility and leads to their rapid elimination by the monocyte– macrophage system of the spleen.

Applications:

Using BS3 agent, the treatment is less harsh and leads to the crosslinking of specific proteins such as Band 3.56 BS3-treated erythrocytes are less rigid than GA-treated cells and thus appear more suitable for clinical use. It is also possible to enhance erythrocyte senescence by using a BS3/ZnCl2 combination which is described to induce autologous Iggy binding and complement fixation (opsonisation), thus favouring the phagocytosis of ZnCl2/BS3-treated cells by macrophages.

The two main applications of the RES-targeting strategy also be used to target the spleen and the liver[10]. GA reacts Drug Design, Development and Therapy 2016:10 submit your manuscript Dove press 670 Bureaux et al extensively with proteins in the erythrocyte membrane.

The resulting erythrocytes are characterized by an extreme rigidity compromising their use for in vivo applications. Using BS3 agent, the treatment is less harsh and leads to the crosslinking of specific proteins such as Band 3.56 BS3-treated erythrocytes are less rigid than GA-treated cells and thus appear more suitable for clinical use. It is also possible to enhance erythrocyte senescence by using a BS3/ZnCl2 combination which is described to induce autologous IgG binding and complement fixation (opsonisation), thus favouring the phagocytosis of ZnCl2/BS3-treated cells by macrophages.

Conclusion

The application of resealed erythrocytes in clinical settings is the subject of this review. The use of resealed erythrocytes appears promise for a safe and certain administration of diverse medications for both passive and active targeting, notwithstanding the large range of potential therapeutic uses outlined by laboratory tests. To become a regular medication distribution system, the idea must be further optimized. The distribution of biopharmaceuticals, proteins, and steroids can all be covered by the same idea. The International Journal of Pharmaceutical Sciences Review and Research 305 uses

resealed erythrocytes as a medication delivery system target. But for the idea to become a personalized medication distribution system, more optimization is required. The majority of research in this field is ongoing and at the in vitro stage. Erythrocyte carriers are now considered "Nano Devices in the field of Nanotechnology" due to their enormous potential. Erythrocyte carriers are currently considered "Nano Devices in the field of Nanotechnology" due to their enormous potential and prospective. Erythrocyte carriers are now considered "Nano Devices in the field of Nanotechnology" due to their enormous potential.

Author contributions

All authors are contributed equally.

Financial support

None

Declaration of Competing Interest

The authors have no conflicts of interest to declare.

Acknowledgements

None

References

1. Shavi GV, Doijad RC, Deshpande PB, Manvi F, Meka SR, Udupa N, Omprakash R, Dhirendra K. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010 Apr 1;23(2):194-200. https://pubmed.ncbi.nlm.nih.gov/20363699
2. Sawant KK, Soni HN, Murthy RS. Investigation on resealed erythrocytes as carriers for 5-fluorouracil. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2001;63(2):105-9.
3. Kumar A, Verma M, Jha KK. Resealed Erythrocytes as a Carrier for Drug Targeting: A Review. The pharma innovation. 2012 Apr 1;1(2, Part A):8. https://doi.org/10.1111/j.1365-2362.1986.tb01305.x
4. Suryasagar G, Bhargavi S, Kanakaiah B, Sowmya DK, Naresh M, Nama S, Rao CB. A review ON resealed erythrocytes. Int. J. Biol. Pharmaceut. Res.. 2013;4:290-6. http://www.ijbpr.com/doi/MjM4a2FsYWkxNDc4NTIzNjk=
5. Deepthi B, Varun D, Gopal PN, Rao CH, Sumalatha G. Super porous hydrogels–Supreme drug delivery. Research Journal of Pharmacy and Technology. 2011;4(8):1182-8.
6. Mitchell DH, James GT, Kruse CA. Bioactivity of electric field-pulsed human recombinant interleukin-2 and its encapsulation into erythrocyte carriers. Biotechnology and applied biochemistry. 1990 Jun;12(3):264-75.
7. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent.
8. Darghouth D, Koehl B, Heilier JF2011, *et al.* Alterations of red blood cell metabolome in overhydrated hereditary stomatocytosis. *Haematologica.* 96(12):1861–1865.
9. Tiffert T, Bookchin RM, Lew VL, Bernhardt I, Ellory JC. Red cell membrane transport in health and disease. https://link.springer.com/book/10.1007/978-3-662-05181-8
10. Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G, Conaldi PG, Magnani M. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. Journal of controlled release. 2011 Sep 25;154(3):306-13.
11. Cremel M, Guérin N, Horand F, Banz A, Godfrin Y. Red blood cells as innovative antigen carrier to induce specific immune tolerance. International journal of pharmaceutics. 2013 Feb 25;443(1-2):39-49. https://www.sciencedirect.com/science/article/abs/pii/S0378517313000082?via%3Dihub
12. Godfrin Y, Bertrand Y. L-asparaginase Introduced into Erythrocytes for the Treatment of Leukaemia (ALL). BioMedES. 2006;1(1):10-3.
13. De Windt TS, Niemansburg SL, Vonk LA, van Delden JM, Roes KC, Dhert WJ, Saris DB, Bredenoord AL. Ethics in musculoskeletal regenerative medicine; guidance in choosing the appropriate comparator in clinical trials. Osteoarthritis and cartilage. 2019 Jan 1;27(1):34-40. *https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-clinical-aspects-related-tissue-engineered-products_en.pdf*
14. Lewis DA, Alpar HO. Therapeutic possibilities of drugs encapsulated in erythrocytes. International journal of pharmaceutics. 1984 Dec 1;22(2-3):137-46.
15. Jaitely V, Kanaujia P, Venkatesan N, Jain S, Vyas SP. Resealed erythrocytes: drug carrier potentials and biomedical applications. Indian Drugs. 1996;33(12):589-94.
16. Jain S, Jain SK, Dixit VK. Erythrocytes based delivery of isoniazid: preparation and in-vitro characterization. Indian Drugs. 1995;32(10):471-6.